Citations

Clear

941 citation(s) found for "Tefferi, A".

Cladribine therapy for advanced and indolent systemic mastocytosis: Mayo Clinic experience in 42 consecutive cases
Tefferi, Ayalew , Kittur, Jaya, Farrukh, Faiqa, Begna, Kebede H. , Patnaik, Mrinal M. , Al‐Kali, Aref , Elliott, Michelle A. , Reichard, Kaaren K. , Gangat, Naseema , Pardanani, Animesh

Mayo Clinic

British Journal of Haematology | November 3, 2021 | Volume: 196 | Issue: 4 | Pages: 975-983

10.1111/bjh.17932 | PMID 34729775 Get It

Summary We describe our single institution experience with cladribine therapy in 42 patients with systemic mastocytosis (SM): 22 advanced (adv‐SM; median age 65 years, 68% males) and 20 indolent/smouldering SM (ISM/SSM; median age 56 years, 45% males); subcategories included eight aggressive, 13 associated with another haematological neoplasm, one mast cell leukaemia, 17 ISM and three SSM. Overall/major response rates were 77%/45% for adv‐SM and 70%/60% for ISM/SSM, and median (range) duration of response 10 (4–75) and 46 (4–140) months respectively. A >50% reduction in bone marrow mast cell burden and serum tryptase level was documented in 63% and 67% of patients with adv‐SM and 50% and 46% with ISM/SSM respectively. The presence of KIT proto‐oncogene, receptor tyrosine kinase ( KIT ) D816V predicted response in adv‐SM: 17 (90%) of 19 with and none of three without the mutation responded ( P < 0·01). Treatment‐emergent adverse events were mostly limited to transient cytopenias: Grade 3/4 neutropenia, thrombocytopenia, or lymphopenia occurred in 27%, 27% and 27% of patients with adv‐SM, and 5%, 5% and 30% with ISM/SSM respectively. The present study provides practical information that might be considered when making treatment choices between cladribine and newer KIT‐targeted therapies and identifies the absence of KIT D816V as a potential marker of cladribine resistance in advanced SM; the latter observation needs confirmation in a larger study.
Prediction of early (4‐week) mortality in acute myeloid leukemia with intensive chemotherapy
Sasaki, Koji , Kadia, Tapan M. , Begna, Kebede H. , DiNardo, Courtney D. , Borthakur, Gautam , Short, Nicholas J. , Daver, Naval , Jabbour, Elias , Garcia‐Manero, Guillermo , Montalban‐Bravo, Guillermo , Pierce, Sherry , Konopleva, Marina , Tefferi, Ayalew , Kantarjian, Hagop M. , Kadia, Tapan M , Begna, Kebede , Daver, Naval , Jabbour, Elias , Garcia-Manero, Guillermo , Bravo, Guillermo Montalban , Konopleva, Marina , Ravandi, Farhad , Tefferi, Ayalew , Sasaki, Koji , Borthakur, Gautam , DiNardo, Courtney , Short, Nicholas , Kantarjian, Hagop , Jain, Nitin , Masárová, Lucia

Mayo Clinic

American Journal of Hematology | October 30, 2021 | Volume: 97 | Issue: 1 | Pages: 68-78

10.1002/ajh.26395 | PMID 34716921 Get It

AbstractThe progress with intensive chemotherapy and supportive care measures has improved survival in patients with newly diagnosed acute myeloid leukemia (AML). Given the recent development of effective low intensity therapies, an optimal decision on the therapy intensity may improve survival through the avoidance of early mortality. We reviewed the outcome of 3728 patients with newly diagnosed AML who received intensive chemotherapy between August 1980 and May 2020. Intensive chemotherapy was defined as a cumulative cytarabine dose ≥ 700 mg/m2 during induction therapy. We divided the whole cohort into a training and validation group at a 3:1 ratio. The population was divided into a training (2790 patients) and a validation cohort (938 patients). The median age was 55 years (range, 15‐99). Among them, 442 patients (12%) had core‐binding factor AML. Binary logistic regression identified older age, worse performance status, hyperbilirubinemia, elevated creatinine, hyperuricemia, cytogenetic abnormalities other than CBF and ‐Y, and pneumonia as adverse prognostic factors for an early 4‐week mortality. This risk classification for early mortality was verified in the validation cohort of patients. In the validation cohort of more recently treated patients from 2000 to 2017, the 4‐week mortality rates with intensive chemotherapy were 2%, 14%, and 50% in the low‐, high‐, and very high‐risk group, respectively. The mortality rates with low intensity therapies were 3%, 9%, and 20%, respectively. The risk classification guides treatment intensity by the assessment of age, frailty, organ dysfunction, cytogenetic abnormality, and infection to avoid early mortality.
A population‐based study of outcomes in polycythemia vera, essential thrombocythemia, and primary myelofibrosis in the United States from 2001 to 2015: Comparison with data from a Mayo Clinic single institutional series
Smith, Caleb J. , Thomas, John W., Ruan, Gordon , Hyun, Meredith , Bansal, Radhika , McLaughlin, N , Pardanani, Animesh , Gangat, Naseema , Szuber, Natasha , Tefferi, Ayalew , Hyun, Meredith C , McLaughlin, Nicole , Szuber, Natasha , Shah, Mithun V , Tefferi, Ayalew , Go, Ronald S. , Goyal, Gaurav , Shah, Meera

Mayo Clinic

American Journal of Hematology | October 20, 2021 | Volume: 96 | Issue: 12 | Pages: No page available

10.1002/ajh.26377 | PMID 34661932 Get It

Genetic features and clinical outcomes of patients with isolated and comutated DDX41 -mutated myeloid neoplasms
Nanaa, Ahmad , Viswanatha, David S., Foran, James M. , Badar, Talha , Sproat, Lisa, He, Rong , Nguyen, Phuong L., Salama, Mohamad E., Greipp, Patricia T. , Gangat, Naseema , Tefferi, Ayalew , Litzow, Mark R. , Mangaonkar, Abhishek A. , Patnaik, Mrinal M. , Al‐Kali, Aref , Nanaa, Ahmad , Viswanatha, David, Badar, Talha , He, Rong , Greipp, Patricia, Litzow, Mark R. , Shah, Mithun V , Patnaik, Mrinal , Greipp, Patricia T , Alkhateeb, Hassan B. , Jevremović, Dragan , Shah, Meera

Mayo Clinic

Blood Advances | October 18, 2021 | Volume: 6 | Issue: 2 | Pages: 528-532

10.1182/bloodadvances.2021005738 | PMID 34644397 Get It

Abstract DDX41 mutations (germline and somatic) are associated with late onset myelodysplastic syndromes/acute myeloid leukemia (MDS/AML). Myeloid neoplasms (MN) with germline predisposition was identified as a distinct category in the 2016 WHO classification revision, including MN with germline DDX41 mutation. We retrospectively analyzed the molecular findings and clinical characteristics of thirty-three DDX41-mutated (mDDX41) patients at our institution. We identified 14 distinct pathogenic DDX41 variants in 32 patients and 8 DDX41 variants of unknown significance (VUS) in 9 patients. Five (16%) patients had a second DDX41 somatic mutation p.R525H and 13 (40%) had at least one additional oncogenic co-mutation in other genes. The median age at the time of diagnosis was 66 years, with male predominance (72%) and the majority of patients had normal cytogenetics (91%). Two-year overall survival (OS) was 86% and 6 (21%) MDS/AML patients with relatively preserved hematopoietic function were observed without further intervention. In comparison to AML patients with prognostically more favorable subtypes [t(8;21), n=27 and inv(16), n=40], mDDX41 patients in our cohort showed similarly favorable OS. Our study highlights that mDDX41-MN patients often have an indolent course and mDDX41-AML has comparable OS to favorable-risk AML.
JAK2 wild-type erythrocytosis associated with sodium-glucose cotransporter 2 inhibitor therapy
Gangat, Naseema , Al‐Kali, Aref , Pardanani, Animesh , Tefferi, Ayalew , Szuber, Natasha , Alkhateeb, Hassan B.

Mayo Clinic

Blood | October 15, 2021 | Volume: 138 | Issue: 26 | Pages: 2886-2889

10.1182/blood.2021013996 | PMID 34653249 Get It

High‐oxygen‐affinity hemoglobinopathy‐associated erythrocytosis: Clinical outcomes and impact of therapy in 41 cases
Gangat, Naseema , Oliveira, Jennifer L. , Hoyer, James D., Patnaik, Mrinal M. , Pardanani, Animesh , Tefferi, Ayalew , Herrick, Jennifer L.

Mayo Clinic

American Journal of Hematology | October 11, 2021 | Volume: 96 | Issue: 12 | Pages: 1647-1654

10.1002/ajh.26375 | PMID 34633117 Get It

AbstractWe describe presenting features, treatment strategies, and follow‐up events involving 41 patients (median age 39 years, range 1–81; 54% males) with high oxygen affinity (HOA) hemoglobinopathy‐associated erythrocytosis, seen at our institution (1973–2020). Thirty‐four (83%) patients carried β‐chain (13 Malmo, 4 Olympia, 3 San Diego, 2 Wood) and 7 (17%) α‐chain (4 Dallas and one each Columbia‐Missouri, Jackson, and Wayne) variants. Median (range) hemoglobin (Hgb)/hematocrit (Hct), serum erythropoietin and p50 were 18 g/dL/52.9% (16–21.9/48–66), 10.4 mIU (4–36.3), and 20 mmHg (12–25), respectively. Family history was documented in 24 patients and history of thrombosis in two (5%). Treatment included phlebotomy in 23 and antiplatelet therapy in 21 patients. At a median follow‐up of 10 years, 23 (56%) patients reported one or more symptoms that were thought to be related to their increased Hct while thrombosis was documented in 10 (24%) patients. Neither Hgb/Hct level nor active phlebotomy showed a significant correlation with either thrombotic or nonthrombotic symptoms (p > .1 in all instances). Among 23 pregnancies recorded, 78% resulted in live births and no fetal loss was attributed to erythrocytosis. The current study does not implicate Hgb/Hct level as a major contributor of morbidity in HOA hemoglobinopathy‐associated erythrocytosis and suggests limited therapeutic value for phlebotomy.
Cerebral venous thrombosis and myeloproliferative neoplasms: A three‐center study of 74 consecutive cases
Gangat, Naseema , Betti, Silvia, Farrukh, Faiqa, Barbui, Tiziano , Vannucchi, Alessandro M. , Stefano, Valerio De , Tefferi, Ayalew , Barbui, Tiziano , De Stefano, Valerio , Tefferi, Ayalew , Vannucchi, Alessandro M , Guglielmelli, Paola , Betti, Silvia, Carobbio, Alessandra

Mayo Clinic

American Journal of Hematology | August 28, 2021 | Volume: 96 | Issue: 12 | Pages: 1580-1586

10.1002/ajh.26336 | PMID 34453762 Get It

AbstractThe recent association of cerebral venous thrombosis (CVT) with COVID‐19 vaccinations prompted the current retrospective review of 74 cases of CVT (median age = 44 years, range 15–85; 61% females) associated with myeloproliferative neoplasms (MPNs), seen at the Mayo Clinic, Catholic University of Rome, and University of Florence, between 1991 and 2021. Disease‐specific frequencies were 1.3% (39/2893), 1.2% (21/1811) and 0.2% (3/1888) for essential thrombocythemia, polycythemia vera and primary myelofibrosis, respectively. Cerebral venous thrombosis occurred either prior to (n = 20, 27%), at (n = 32, 44%) or after (n = 22) MPN diagnosis. A total of 72% of patients presented with headaches. Transverse (51%), sagittal (43%) and sigmoid sinuses (35%) were involved with central nervous system hemorrhage noted in 10 (14%) patients. In all, 91% of tested patients harbored JAK2V617F. An underlying thrombophilic condition was identified in 19 (31%) cases and history of thrombosis in 10 (14%). Treatment for CVT included systemic anticoagulation alone (n = 27) or in conjunction with aspirin (n = 24), cytoreductive therapy (n = 14), or both (n = 9). At a median follow‐up of 5.1 years (range 0.1–28.6), recurrent CVT was documented in three (4%) patients while recurrent arterial and venous thromboses and major hemorrhage were recorded in 11%, 9% and 14%, respectively. Follow‐up neurological assessment revealed headaches (n = 9), vision loss (n = 1) and cognitive impairment (n = 1). The current study lends clarity to MPN‐associated CVT and highlights its close association with JAK2V617F, younger age and female gender. Clinical features that distinguish COVID vaccine‐related CVT from MPN‐associated CVT include, in the latter, lower likelihood of concurrent venous thromboses and intracerebral hemorrhage; as a result, MPN‐associated CVT was not fatal.
Outcomes of venetoclax‐based therapy in chronic phase and blast transformed chronic myelomonocytic leukemia
Saliba, Antoine N. , Litzow, Mark R. , Gangat, Naseema , Al‐Kali, Aref , Foran, James M. , Palmer, Jeanne , Mangaonkar, Abhishek A. , Tefferi, Ayalew , Patnaik, Mrinal M. , Saliba, Antoine N. , Palmer, Jeanne M., Mangaonkar, Abhishek A. , Tefferi, Ayalew , Patnaik, Mrinal , Saliba, Antoine N , Saliba, Antoine N , Hogan, William J.

Mayo Clinic

American Journal of Hematology | August 24, 2021 | Volume: 96 | Issue: 11 | Pages: No page available

10.1002/ajh.26334 | PMID 34428328 Get It

Clinical and molecular predictors of fibrotic progression in essential thrombocythemia: A multicenter study involving 1607 patients
Loscocco, Giuseppe Gaetano , Guglielmelli, Paola , Gangat, Naseema , Rossi, Elena, Mannarelli, Carmela, Betti, Silvia, Maccari, Chiara , Ramundo, Francesco , Jadoon, Yamna, Gesullo, Francesca, Ceglie, Sara , Pardanani, Animesh , Tefferi, Ayalew , Loscocco, Giuseppe Gaetano , Pardanani, Animesh , De Stefano, Valerio , Tefferi, Ayalew , Vannucchi, Alessandro M , Guglielmelli, Paola , Betti, Silvia, Paoli, Chiara, Stefano, Valerio De , Vannucchi, Alessandro M.

Mayo Clinic

American Journal of Hematology | August 23, 2021 | Volume: 96 | Issue: 11 | Pages: 1472-1480

10.1002/ajh.26332 | PMID 34424575 Get It

Abstract The current retrospective study involving a total of 1607 patients was designed to identify clinical and molecular variables that were predictive of inferior myelofibrosis‐free survival (MFS) in WHO‐defined essential thrombocythemia (ET), utilizing three independent patient cohorts: University of Florence, Italy ( n = 718); Mayo Clinic, USA ( n = 479) and Policlinico Gemelli, Catholic University, Rome, Italy ( n = 410). The Florence patient cohort was first examined to identify independent risk factors for MFS, which included age > 60 years (HR 2.5, 95% CI 1.3–4.9), male sex (2.1, 1.2–3.9), palpable splenomegaly (2.1, 1.2–3.9), CALR 1/1‐like or MPL mutation (3.4, 1.9–6.1) and JAK2 V617F variant allele frequency > 35% (4.2, 1.6–10.8). Subsequently, an operational molecular risk category was developed and validated in the other two cohorts from Mayo Clinic and Rome: “high molecular risk” category included patients with JAK2 V617F VAF >35%, CALR type 1/1‐like or MPL mutations; all other driver mutation profiles were assigned to “low molecular risk” category. The former, compared to the latter molecular risk category, displayed significantly higher risk of fibrotic transformation: Florence cohort with respective fibrotic transformation risk rates of 8% vs. 1.2% at 10 years and 33% vs. 8% at 20 years ( p < 0.001; HR 6.1; 95% CI 3.2–11.7); Mayo Cohort, 16% vs. 7% at 10 years and 44% vs. 25% at 20 years ( p < 0.001; HR 2.5; 95% CI 1.6–4.1); and Rome cohort 7.8% vs. 4.6% at 10 years and 31.2% vs. 7.1% at 20 years ( p = 0.007, HR 2.7; 95% CI 1.3–5.8). The present study provides practically useful risk signals for fibrotic transformation in ET and facilitates identification of patients who require close monitoring and appropriate counseling.
Spectrum of hematological malignancies, clonal evolution and outcomes in 144 Mayo Clinic patients with germline predisposition syndromes
Martin, Emma C. St. , Mangaonkar, Abhishek A. , Khan, Shakila P. , Kohorst, Mira A. , Joshi, Avni Y. , Olteanu, Horatiu , Moyer, Ann M. , Al‐Kali, Aref , Tefferi, Ayalew , Chen, Dong , Wudhikarn, Kitsada , Viswanatha, David S., He, Rong , Nguyen, Phuong L., Oliveira, Jennifer L. , Gangat, Naseema , Patnaik, Mrinal M. , Herrick, Jennifer L. , St Martin, Emma C , Mangaonkar, Abhishek A. , Tefferi, Ayalew , Chen, Dong , Viswanatha, David, He, Rong , Patnaik, Mrinal , Ferrer, Alejandro , Hogan, William J. , Go, Ronald S. , Ketterling, Rhett P. , Lasho, Terra L.

Mayo Clinic

American Journal of Hematology | August 14, 2021 | Volume: 96 | Issue: 11 | Pages: 1450-1460

10.1002/ajh.26321 | PMID 34390506 Get It

AbstractGermline predisposition syndromes (GPS) result from constitutional aberrations in tumor suppressive and homeostatic genes, increasing risk for neoplasia in affected kindred. In this study, we present clinical and genomic data on 144 Mayo Clinic patients with GPS; 59 evaluated prospectively using an algorithm‐based diagnostic approach in the setting of a dedicated GPS/ inherited bone marrow failure syndrome (IBMFS) clinic. Seventy‐two (50%) patients had IBMFS (telomere biology disorders‐32,Fanconi anemia‐18, Diamond Blackfan Anemia – 11, congenital neutropenia–5, Schwachman‐Diamond Syndrome‐5 and Bloom Syndrome‐1), 27 (19%) had GPS with antecedent thrombocytopenia (RUNX1‐FPD‐15, ANKRD26‐6, ETV6‐2, GATA1‐1, MPL‐3), 28 (19%) had GPS without antecedent thrombocytopenia (GATA2 haploinsufficiency‐16, DDX41‐10, CBL‐1 and CEBPA‐1) and 17 (12%) had general cancer predisposition syndromes (ataxia telangiectasia‐7, heterozygous ATM variants‐3, CHEK2‐2, TP53‐2, CDK2NA‐1, NF1‐1 and Nijmegen Breakage Syndrome‐1). Homozygous and heterozygous ATM pathogenic variants were exclusively associated with lymphoproliferative disorders (LPD), while DDX41 GPS was associated with LPD and myeloid neoplasms. The use of somatic NGS‐testing identified clonal evolution in GPS patients, with ASXL1, RAS pathway genes, SRSF2 and TET2 being most frequently mutated. Fifty‐two (91%) of 59 prospectively identified GPS patients had a change in their management approach, including additional GPS‐related screening in 42 (71%), referral for allogenic HSCT workup and screening of related donors in 16 (27%), medication initiation and selection of specific conditioning regimens in 14 (24%), and genetic counseling with specific intent of fertility preservation and preconceptual counseling in 10 (17%) patients; highlighting the importance of dedicated GPS screening, detection and management programs for patients with hematological neoplasms.